 SAN DIEGO, CA, and ANAHEIM, CA, Sept. 08, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- Recro Pharma, Inc. Recro; NASD: REPH, a contract development and manufacturing organization CDMO dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc. BioCorRx; OTCQB: BICX, a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the expansion of the companies ongoing relationship with the signing of a new development and manufacturing agreement. Under terms of the new agreement, Recro will provide analytical validation services and cGMP manufacturing of registrational batches of BICX104 to support BioCorRxs potential filing of a New Drug Application NDA for BICX104 with the U.S. Food and Drug Administration FDA. 